General Information of Drug (ID: DMXLHIO)

Drug Name
V158411 Drug Info
Synonyms
1174664-88-0; 1-Benzyl-N-(5-{5-[3-(Dimethylamino)-2,2-Dimethylpropoxy]-1h-Indol-2-Yl}-6-Oxo-1,6-Dihydropyridin-3-Yl)-1h-Pyrazole-4-Carboxamide; VER-00158411; 1-Benzyl-N-(5-(5-(3-(dimethylamino)-2,2-dimethylpropoxy)-1H-indol-2-yl)-6-oxo-1,6-dihydropyridin-3-yl)-1H-pyrazole-4-carboxamide; VER-158411; SCHEMBL950079; BCP25319; HY-18942; CS-0014655; Q27455647; V 158411; V-158411; VER00158411; VER 00158411; VER-00158411; 1-benzyl-N-[5-[5-[3-(dimethylamino)-2,2-dimethylpropoxy]-1H-indol-2-yl]-6-oxo-1H-pyridin-3-yl]pyrazole-4-carboxamide; 5CV
Indication
Disease Entry ICD 11 Status REF
Triple negative breast cancer 2C60-2C65 Investigative [1]
Cross-matching ID
PubChem CID
44198296
TTD Drug ID
DMXLHIO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [3]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [4]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
LY2606368 DM4XMF7 Ovarian cancer 2C73 Phase 2 [6]
LY2880070 DMADEHZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [8]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [9]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [11]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [2]

References

1 Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570.
2 Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discov. 2018 Feb;23(2):144-153.
3 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
4 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
5 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
8 National Cancer Institute Drug Dictionary (drug id 730054).
9 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
10 Clinical pipeline report, company report or official report of AstraZeneca (2009).
11 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
12 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.